Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Race Oncology Ltd. ( (AU:RAC) ) has shared an update.
Racura Oncology Ltd has applied to the ASX for quotation of 1,067,816 new ordinary fully paid shares, with an issue date of 23 April 2026. The newly issued securities arise from the exercise or conversion of existing options or other convertible securities, modestly expanding the company’s share base and potentially strengthening its capital position for ongoing oncology development activities.
This incremental issuance may slightly dilute existing shareholders but indicates continued investor engagement with Racura Oncology’s equity, supporting its ability to fund operational and research priorities. The move underscores the company’s reliance on capital markets to advance its cancer-focused pipeline and maintain its presence within the competitive biotech sector.
More about Race Oncology Ltd.
Racura Oncology Ltd is an Australian-listed biotechnology company focused on oncology, developing therapies aimed at treating cancer. The company is listed on the ASX under the ticker RAC and raises capital and manages its shareholder base through regular equity market transactions.
Average Trading Volume: 207,047
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$615.7M
Learn more about RAC stock on TipRanks’ Stock Analysis page.